Fig. 1: Kaplan–Meier analysis of survival outcomes in patients with intermediate-risk MDS.

(A) Kaplan–Meier curves of OS for patients with intermediate-risk MDS according to their IPSS-R value (3.5, 4.0, or 4.5). OS was better among patients with IPSS-R 3.5 as compared with IPSS-R > 3.5 (p = 0.039 by the log-rank test). (B) Kaplan-Meier curve of OS among patients with intermediate-risk MDS who received AZA (n = 166), as compared with patients who did not (n = 302). Median OS of the patients who received AZA (32.4 months [95% CI 25.2–39.6]) was similar to patients who did not receive AZA (29.0 months [23.9–34.1]); p = 0.291 by the log-rank test. (C) Kaplan-Meier curve of LFS among patients with intermediate-risk MDS who received AZA (n = 166), as compared with patients who did not (n = 302). Median LFS was 28.0 months (95% CI 19.0–37.0) for the AZA group and 26.0 months (21.8–30.2) for the non-AZA-treated group (p = 0.188). MDS myelodysplastic syndrome, OS overall survival, IPSS-R revised international prognostic scoring system, AZA azacitidine, LFS leukemia-free survival.